AdvanCell Presents Updated Phase 1 Results on ADVC001 at ESMO 2026 with Encouraging Long-term Data
With a median follow-up of over 14 months, ADVC001, a novel Lead-212 PSMA therapy, continues…
DesignQ Developer23 October 2026
AdvanCell Establishes U.S. Global Headquarters and Secures Flagship Manufacturing Facility in Greater Boston to Drive Growth Strategy
New 128,000-square-foot facility in Andover will serve as U.S. global headquarters and future manufacturing center…
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need
Brisbane, Australia and Boston, USA – February 2, 2026 – AdvanCell, a clinical-stage radiopharmaceutical company…
DesignQ Developer2 February 2026
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at…
DesignQ Developer2 December 2025
AdvanCell presenting at the American Association for Cancer Research (AACR) Annual Meeting 2025
Preclinical evaluation and preliminary human imaging of a novel 212Pb-based, PSMA-targeted radioligand, 212Pb-ADVC001, for prostate…
DesignQ Developer28 April 2025
Pb212 PSMA vs Ac225 PSMA from biology to supply Alfred Morgenstern PhD Joint Research Centre Karlsruhe Germany
Source: UroToday PSMA & Beyond: Prof Alfred Morgenstern’s ‘212Pb-PSMA vs 225Ac-PSMA from Supply to Biology’…
DesignQ Developer21 April 2025
AdvanCell awarded $18M in Federal funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’
AdvanCell proudly announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers…
DesignQ Developer14 April 2025
TheraPb Phase Ib/IIa Dose Escalation and Expansion Study of [212Pb]Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer
Despite an increase in the number of approved therapies for metastatic castration- resistant prostate cancer…
DesignQ Developer13 February 2025
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the…
DesignQ Developer10 February 2025
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing Sydney, Australia – 3 February 2025…
DesignQ Developer3 February 2025
